Publications

• Unpacking President Trump’s New Executive Order on Prescription Drug Pricing
  24 April 2025
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Winston M. Paes
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Melissa Runsten
  ,
  Jacob W. Stahl
  ,
  Abby Draper
  ,
  Zoe Jacoby
  ,
  Kaitlyn McGill
  ,
  Adriana Kranjac Rielly
• Proposed Expansion of California Healthcare Transaction Oversight Takes Aim at Private Equity
  25 March 2025
  Andrew L. Bab
  ,
  Spencer K. Gilbert
  ,
  Kevin Rinker
  ,
  Kim T. Le
  ,
  Mackenzie Mendolla
• California Legislature Again Seeks to Restrict Private Equity Investments in Healthcare
  28 February 2025
  Andrew L. Bab
  ,
  Kevin Rinker
  ,
  Kim T. Le
  ,
  Hannah R. Levine
  ,
  Mackenzie Mendolla
• Top 10 Healthcare and Life Sciences Issues to Watch in 2025
  10 January 2025
  Andrew L. Bab
  ,
  Tim Cornell
  ,
  Avi Gesser
  ,
  Mark P. Goodman
  ,
  Ted Hassi
  ,
  Erez Liebermann
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Michael Schaper
  ,
  Jane Shvets
  ,
  Patrick Taylor
  ,
  Erica S. Weisgerber
  ,
  Carter Burwell
  ,
  Kim T. Le
  ,
  Leah Martin
  ,
  Melissa Runsten
  ,
  Jacob W. Stahl
  ,
  Adam Aukland-Peck
  ,
  HJ Brehmer
  ,
  Lillian Clark
  ,
  Zoe Jacoby
  ,
  Adriana Kranjac Rielly
  ,
  Chaim Lapp
  ,
  Hannah R. Levine
  ,
  Kaitlyn McGill
  ,
  Adam C. Saunders
  ,
  Abby Draper
  ,
  Mackenzie Mendolla
• California Lawmakers Target Private Equity and Hedge Fund Investment in Healthcare Facilities
  23 February 2024
  Andrew L. Bab
  ,
  Kevin Rinker
  ,
  Kim T. Le
  ,
  Hannah R. Levine
• Private Equity Report: 2024 Outlook
  February 2024
  Christopher Anthony
  ,
  Katherine Ashton
  ,
  Andrew L. Bab
  ,
  Paul S. Bird
  ,
  Dominic Blaxill
  ,
  Ezra Borut
  ,
  Geoffrey P. Burgess
  ,
  Andrew J. Ceresney
  ,
  Charu A. Chandrasekhar
  ,
  Luke Dembosky
  ,
  E. Drew Dutton
  ,
  Jane Engelhardt
  ,
  Avi Gesser
  ,
  Nia I. Goodman
  ,
  David Grosgold
  ,
  Jyotin Hamid
  ,
  Ted Hassi
  ,
  Morgan J. Hayes
  ,
  Peter J. Irwin
  ,
  Eric T. Juergens
  ,
  Robert B. Kaplan
  ,
  M. Natasha Labovitz
  ,
  Jonathan F. Lewis
  ,
  Sidney P. Levinson
  ,
  Andrew M. Levine
  ,
  Erez Liebermann
  ,
  Timothy McIver
  ,
  Maura Kathleen Monaghan
  ,
  Edwin Northover
  ,
  Brett M. Novick
  ,
  Marc Ponchione
  ,
  Ryan T. Rafferty
  ,
  Natalie L. Reid
  ,
  Julie M. Riewe
  ,
  Kevin Rinker
  ,
  Samantha J. Rowe
  ,
  Paul D. Rubin
  ,
  Michael Schaper
  ,
  Kevin M. Schmidt
  ,
  Scott B. Selinger
  ,
  Aly Love (f/k/a Simons)
  ,
  Thomas Smith
  ,
  Kristin A. Snyder
  ,
  Steven J. Slutzky
  ,
  Ramya S. Tiller
  ,
  Patricia Volhard
  ,
  Erica S. Weisgerber
  ,
  Kyra K. Bromley
  ,
  Alison E. Buckley-Serfass
  ,
  Jennifer R. Cestaro
  ,
  Stuart Hammer
  ,
  Jin-Hyuk Jang
  ,
  Wen-Wei Lai
  ,
  Michael P. McGuigan
  ,
  Sheena Paul
  ,
  Melissa Runsten
  ,
  Tricia Bozyk Sherno
  ,
  Ulysses Smith
  ,
  Sergio Torres
  ,
  Elie J. Worenklein
  ,
  Adam Aukland-Peck
  ,
  Josephine Chen
  ,
  Perpétua B. Chéry
  ,
  Paul Eastham
  ,
  Isabelle Glimcher
  ,
  Yiran Ji
  ,
  Maryam Kanna
  ,
  Leah Martin
  ,
  Sophie Michalski
  ,
  Diana Moise
  ,
  David J. Swiedler
  ,
  Perri M. Weinstein
  ,
  Nathan R. Hogan
• Chevron Under Fire: What Healthcare and Life Sciences Investors Should Know
  19 January 2024
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Melissa Runsten
  ,
  Jacob W. Stahl
  ,
  Adam Aukland-Peck
  ,
  Zoe Jacoby
  ,
  Adriana Kranjac Rielly
  ,
  Kaitlyn McGill
• California’s Office of Health Care Affordability Finalizes Health Care Transaction Notice Regulations
  12 January 2024
  Andrew L. Bab
  ,
  Spencer K. Gilbert
  ,
  Kevin Rinker
  ,
  Matthew M. Delja
  ,
  Kim T. Le
  ,
  Hannah R. Levine
• Top 10 Healthcare and Life Sciences Issues to Watch in 2024
  4 January 2024
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Ted Hassi
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Michael Schaper
  ,
  Erica S. Weisgerber
  ,
  Kim T. Le
  ,
  Melissa Runsten
  ,
  Jacob W. Stahl
  ,
  Adam Aukland-Peck
  ,
  Ilya Balabanovsky
  ,
  Margaret Howard
  ,
  Chaim Lapp
  ,
  Hannah R. Levine
  ,
  Zoe Jacoby
  ,
  Kaitlyn McGill
• CMS Announces First Ten Medicare Part D Drugs Subject to Price Negotiations
  6 October 2023
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Kim T. Le
  ,
  Jacob W. Stahl
  ,
  Hannah R. Levine
  ,
  Melissa Runsten
• California Regulators Publish Draft Regulations on Health Care Pre-Transaction Notice Requirements
  29 August 2023
  Andrew L. Bab
  ,
  Kevin Rinker
  ,
  Kim T. Le
  ,
  Hannah R. Levine
• California Seeks to Increase Healthcare Workers’ Minimum Wage to $25/hour
  21 August 2023
  Andrew L. Bab
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Kim T. Le
  ,
  Hannah R. Levine
  ,
  Melissa Runsten
• Artificial Intelligence in Healthcare: Balancing Risks and Rewards
  31 July 2023
  Andrew L. Bab
  ,
  Avi Gesser
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Kim T. Le
  ,
  Tigist Kassahun
  ,
  Hannah R. Levine
  ,
  Melissa Runsten
  ,
  Mengyi Xu
• New York Seeks Review and Approval Authority over Certain Healthcare Transactions
  7 March 2023
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Kim T. Le
  ,
  Hannah R. Levine
• Proceed with Caution: Online Tracking Technologies Pose HIPAA Compliance Risks
  2 March 2023
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Kim T. Le
  ,
  Hannah R. Levine
• Top 15 Healthcare and Life Sciences Issues to Watch in 2023
  9 January 2023
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Michael Schaper
  ,
  Erica S. Weisgerber
  ,
  Kim T. Le
  ,
  Jacob W. Stahl
  ,
  Elie J. Worenklein
  ,
  Samuel J. Allaman
  ,
  Adam Aukland-Peck
  ,
  Hannah R. Levine
  ,
  Melissa Runsten
  ,
  Adam C. Saunders
  ,
  Adrian St. Francis
  ,
  Emily G. Dennan
  ,
  Micah A. Rubin
• Implications of the Inflation Reduction Act for Investors in Life Sciences Companies
  November 2022
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Kim T. Le
  ,
  Jacob W. Stahl
  ,
  Hannah R. Levine
• Private Equity Report Fall 2022, Vol 22, No 3
  November 2022
  Andrew L. Bab
  ,
  Sally Bergmann Hardesty
  ,
  Michael Bolotin
  ,
  Erin Cleary
  ,
  Matthew Dickman
  ,
  Gregory V. Gooding
  ,
  Mark P. Goodman
  ,
  Gareth Hughes
  ,
  Mark Johnson
  ,
  Henry Lebowitz
  ,
  Maurizio Levi-Minzi
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Kevin M. Schmidt
  ,
  Scott B. Selinger
  ,
  Ramya S. Tiller
  ,
  Zhiyan Cao
  ,
  Kim T. Le
  ,
  Jin-Hyuk Jang
  ,
  Tigist Kassahun
  ,
  Hannah R. Levine
  ,
  Keith J. Slattery
  ,
  Sergio Torres
  ,
  Dominique Trudelle
  ,
  Hadel Alfagir
  ,
  David N. Simpser
• Dealmaking Implications of California’s New Healthcare Cost Monitoring Law
  19 August 2022
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Kim T. Le
  ,
  Jacob W. Stahl
  ,
  Hannah R. Levine
• Recent SCOTUS Decisions Impacting Healthcare
  3 August 2022
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Kim T. Le
  ,
  Jacob W. Stahl
  ,
  Adam Aukland-Peck
• FTC Sharpens Focus on Private Equity
  17 June 2022
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Ted Hassi
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Michael Schaper
  ,
  Erica S. Weisgerber
  ,
  Kim T. Le
  ,
  Leah Martin
  ,
  Adam C. Saunders
• California Poised to Grant Attorney General Broad Approval Authority over Healthcare Transactions
  16 June 2022
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Kim T. Le
  ,
  Jacob W. Stahl
  ,
  Hannah R. Levine
• Texas Federal Judge Sides with Providers in “No Surprises Act” Ruling
  1 March 2022
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Kim T. Le
  ,
  Jacob W. Stahl
  ,
  Adam Aukland-Peck
  ,
  Adriana Kranjac Rielly
  ,
  Hannah R. Levine
  ,
  Melissa Runsten
• The American Rescue Plan Act of 2021: Implications for Healthcare and Life Sciences Companies
  12 March 2021
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Kim T. Le
  ,
  Hannah R. Levine
  ,
  Melissa Runsten
  ,
  Benjamin Leb
• Proposed Elimination of Medicaid Rebate Cap Could Negatively Impact Innovator Pharmaceutical Industry
  11 February 2021
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Kim T. Le
  ,
  Melissa Runsten
• Biden Takes Aim at Trump Administration Healthcare Policies
  2 February 2021
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Kim T. Le
  ,
  Melissa Runsten
• Consolidated Appropriations Act: Implications for Healthcare and Life Sciences Companies
  30 December 2020
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Kim T. Le
  ,
  Melissa Runsten
• Law360: M&A Poised For Growth In The Biden Era
  30 November 2020
  Law360
  Jonathan E. Levitsky
  ,
  Kevin Rinker
  ,
  Ted Hassi
  ,
  Peter A. Furci
  ,
  Peter F.G. Schuur
• The Trump Administration’s Final Drug Pricing Hurrah—Will It Last?
  24 November 2020
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Kim T. Le
  ,
  Melissa Runsten
• COVID-19 Vaccines: FDA Regulatory Timeline and Next Steps Prior to Widespread Distribution
  20 November 2020
  Paul D. Rubin
  ,
  Melissa Runsten
  ,
  Kevin Rinker
  ,
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• The Potential Impact of a Biden Administration on Life Sciences, Healthcare, and Consumer Product Companies and Investors
  2 November 2020
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Maura Kathleen Monaghan
  ,
  Jacob W. Stahl
  ,
  Kim T. Le
  ,
  Melissa Runsten
• Trump’s Newest Drug Pricing Executive Order: Still Much More Bark than Bite
  16 September 2020
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Kim T. Le
  ,
  Melissa Runsten
• HHS Announces Additional CARES Act Funding for Qualifying Providers
  4 August 2020
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Kim T. Le
  ,
  Melissa Runsten
• Trump’s New Drug Pricing Executive Orders: Much More Bark Than Bite
  29 July 2020
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• HHS Issues Additional Guidance on Qualifications for CARES Act Funding
  8 May 2020
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• Appropriations for Healthcare Providers Related to COVID-19
  30 April 2020
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• New Appropriation for Healthcare Providers
  24 April 2020
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• HHS Announces Additional Funding for Healthcare Providers Impacted by COVID-19
  23 April 2020
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• HHS Distributing $30 Billion in Grants to Medicare Providers
  10 April 2020
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• CMS Announces Intent to Provide $30 Billion to Medicare Providers
  9 April 2020
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• Update Regarding Public Health and Social Services Emergency Fund
  6 April 2020
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• Present Tense: Allocating the Evolving Risk of COVID-19 in M&A Transactions
  30 March 2020
  Gregory V. Gooding
  ,
  William D. Regner
  ,
  Kevin Rinker
  ,
  Jeffrey J. Rosen
• The Federal Government Throws a Lifeline to Medicare Providers and Suppliers
  30 March 2020
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• CARES Act: Implications for Healthcare and Life Science Companies and Investors
  27 March 2020
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• Indian Pharma: Congress and FDA Continue Scrutiny of Foreign Drug Companies with Heightened Focus on Companies Located in India
  12 February 2020
  Andrew L. Bab
  ,
  Geoffrey P. Burgess
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Suchita Mandavilli Brundage
  ,
  Melissa Runsten
• What the Bipartisan Budget Agreement Means for the Healthcare Industry and Life Sciences Companies
  23 December 2019
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Ted Hassi
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Leah Martin
• Congressional Investigation Highlights Potential Risks for Private Equity Healthcare Investments
  19 September 2019
  Andrew L. Bab
  ,
  Maura Kathleen Monaghan
  ,
  David A. O'Neil
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Kevin M. Schmidt
  ,
  Jacob W. Stahl
• Private Equity Guide to Consumer Product Investing Under the Trump Administration: Food and Drug Administration (FDA) Developments
  18 April 2019
  Andrew L. Bab
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Kevin M. Schmidt
  ,
  Melissa Runsten
• Affordable Care Act Likely to Survive Latest Challenge
  19 December 2018
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• The 2018 Elections: Winners and Losers in the Healthcare Ecosystem
  9 November 2018
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• CMS’ Proposed Part B Price Controls: Hurdles and Unintended Consequences
  5 November 2018
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• CMS’ Proposed Rule Regarding Disclosure of Drug “List Prices” in Television Ads: Needed Transparency or Recipe for Confusion?
  23 October 2018
  Andrew L. Bab
  ,
  David H. Bernstein
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Jared I. Kagan
  ,
  Melissa Runsten
• The White House’s Drug Pricing “Blueprint”
  18 May 2018
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• Private Equity Guide to Life Sciences Investing Under the Trump Administration: Food and Drug Administration (FDA) Developments
  15 March 2018
  Andrew L. Bab
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Melissa Runsten
• The Latest on the Trump Administration’s Drug Pricing Initiatives
  21 February 2018
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• T.H. v. Novartis: Implications for Companies That Have Sold or Are Considering Selling the Rights to Innovator Drugs
  19 January 2018
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Melissa Runsten
  ,
  Jacob W. Stahl
• A Look At Recent Efforts To Contain Health Care Costs
  5 January 2018
  Law360
  Andrew L. Bab
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• How Tax Reform and Other Recent Developments Could Impact the Healthcare Industry
  20 December 2017
  Andrew L. Bab
  ,
  Peter A. Furci
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• New Public and Private Efforts to Contain Healthcare Costs: What it Means for the Healthcare Industry
  20 December 2017
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• Law360: How Tax Reform Could Impact the Health Care Industry
  15 November 2017
  Andrew L. Bab
  ,
  Peter A. Furci
  ,
  Mark P. Goodman
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• The “Tax Cuts and Jobs Act” – How It Impacts the Healthcare Industry
  7 November 2017
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Gary M. Friedman
  ,
  Peter A. Furci
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Jacob W. Stahl
• Where Does Healthcare Reform Stand?
  31 October 2017
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Jacob W. Stahl
• How Section 1332 Waivers Could Impact Health Care Reform
  24 July 2017
  Law 360
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Jacob W. Stahl
• Health Care Winners And Losers From The Better Care Act
  29 June 2017
  Law 360
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Jacob W. Stahl
• The “Better Care Act”: Winners and Losers in the Healthcare Industry
  28 June 2017
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Jacob W. Stahl
• The Senate’s Healthcare Bill – What’s In It?
  28 June 2017
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Jacob W. Stahl
• Finally A Health Care Reform Plan Passes the House – What’s in the Bill and What it Means for the Healthcare Industry
  5 May 2017
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Jacob W. Stahl
• Shining A Light On GOP Plan For Health Care Reform
  7 March 2017
  Law360
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Jacob W. Stahl
• Just a Bit of Clarity – Recent Developments Shine Some Light on Trump and GOP Plans for Healthcare Reform
  27 February 2017
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Kevin Rinker
  ,
  Maura Kathleen Monaghan
  ,
  Jacob W. Stahl
• The Outlook For The Pharmaceutical Industry Under Trump
  12 January 2017
  Law360
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Jacob W. Stahl
• The Outlook On Drug Pricing: At What Cost?
  14 December 2016
  Law360
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Jacob W. Stahl
• Still in the Waiting Room: Outlook for the Healthcare Industry Under the Trump Administration
  15 November 2016
  Andrew L. Bab
  ,
  Gary M. Friedman
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Jacob W. Stahl
• Ninth Circuit Affirms District Court Order to Unwind Hospital Merger
  13 February 2015
  Gary W. Kubek
  ,
  Mark P. Goodman
  ,
  Andrew L. Bab
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Erica S. Weisgerber
• The Inversion Craze: What You Need to Know
  Fall 2014
  Gary M. Friedman
  ,
  Andrew L. Bab
  ,
  Kevin Rinker
• Lot of Inversion Talk, but Do You Know the Basics?
  7 August 2014
  Law360
  Andrew L. Bab
  ,
  Gary M. Friedman
  ,
  Kevin Rinker
• MAC Clauses in the UK and U.S.: Much Ado About Nothing?
  March 2014
  The M&A Lawyer
  Katherine Ashton
  ,
  Kevin Rinker
• MAC Clauses in the UK and U.S.: Much Ado about Nothing?
  Fall 2013
  Katherine Ashton
  ,
  Kevin Rinker
• Imitation Is The Sincerest Form of Flattery: Continued Use of Private Equity Technology in Acquisitions by Strategic Buyers
  Summer/Fall 2012, Vol 13, Number 1
  Kevin Rinker
  ,
  Uri Herzberg
• When Size Does Matter: The SEC’s New Rules on Large Trader Registration May Snare Private Equity
  Winter 2012, Vol. 12, Number 2
  Kevin Rinker
  ,
  Gary E. Murphy
• Recent Developments in the Russian Pharmaceutical Industry
  31 May 2013
  Andrew L. Bab
  ,
  Kevin Rinker
• Imitation Is the Sincerest Form of Flattery: Continued Use of Private Equity Technology in Acquisitions by Strategic Buyers
  January 2013
  The M&A Lawyer
  Kevin Rinker
  ,
  Uri Herzberg
• The Private Equity Report
  Summer/Fall 2012
  Franci J. Blassberg
  ,
  Erin Cleary
  ,
  Guy Lewin-Smith
  ,
  Michael P. Harrell
  ,
  Burt Rosen
  ,
  Robert J. Staffaroni
  ,
  Kevin Rinker
  ,
  Uri Herzberg
  ,
  Jonathan F. Lewis
  ,
  Andrew M. Ostrognai
  ,
  David P. Iozzi
• Imitation Is The Sincerest Form of Flattery: Continued Use of Private Equity Technology in Acquisitions by Strategic Buyers
  Summer/Fall 2012
  Kevin Rinker
  ,
  Uri Herzberg
• Supreme Court Upholds 2010 Patient Protection and Affordable Care Act
  29 June 2012
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
• When Size Does Matter: The SEC's New Rules On Large Trader Registration
  28 June 2012
  Mergers & Acquisitions
  Kevin Rinker
  ,
  Gary E. Murphy
• The SEC Set New Rules On Large Trader Registration
  19 June 2012
  Kevin Rinker
  ,
  Gary E. Murphy
• The Private Equity Report
  Winter 2012
  Matthew E. Kaplan
  ,
  David Innes
  ,
  Alan J. Davies
  ,
  Thomas Smith
  ,
  Kevin Rinker
  ,
  Gary E. Murphy
  ,
  Kenneth J. Berman
  ,
  Andrew M. Ostrognai
  ,
  Jeffrey E. Ross
  ,
  Scott B. Selinger
  ,
  David A. Brittenham
• Supreme Court Rules in Two Pharma Cases
  29 June 2011
  Anne E. Cohen
  ,
  Andrew L. Bab
  ,
  Kevin Rinker
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
• Head of Senate Subcommittee on Antitrust Sounds Alarm on Drug Shortages
  26 May 2011
  Daniel M. Abuhoff
  ,
  Andrew L. Bab
  ,
  Kevin Rinker
• Allocating Financing Risk: Recent Trends in Sponsor-Led Public Company LBOs
  February 2011
  The M&A Lawyer
  Kevin Rinker
• The Private Equity Report
  Spring 2010
  Franci J. Blassberg
  ,
  Guy Lewin-Smith
  ,
  Edwin Northover
  ,
  Matthew D. Saronson
  ,
  Burt Rosen
  ,
  Robert J. Staffaroni
  ,
  Kevin Rinker
  ,
  Jennifer J. Burleigh
  ,
  Gregory J. Lyons
  ,
  Geoffrey Kittredge
  ,
  Peter F.G. Schuur
  ,
  Jonathan Adler
  ,
  Michael Bolotin
• Something Old, New, Borrowed and Blue
  3 August 2009
  The Daily Deal
  Kevin Rinker
• Something Old, New, Borrowed and Blue
  29 July 2009
  The Deal; TheDeal.com
  Kevin Rinker
• The Private Equity Report
  Spring 2009
  Franci J. Blassberg
  ,
  Andrew L. Bab
  ,
  Kenneth J. Berman
  ,
  Gary M. Friedman
  ,
  Richard F. Hahn
  ,
  Peter J. Irwin
  ,
  Marcia L. MacHarg
  ,
  Nicole Levin Mesard
  ,
  Kevin Rinker
  ,
  Matthew D. Saronson
  ,
  Philipp von Holst
• Bridging the Gap
  4 May 2009
  The Daily Deal
  Kevin Rinker
• The Private Equity Report
  Winter 2009
  Franci J. Blassberg
  ,
  Gregory V. Gooding
  ,
  Gary M. Friedman
  ,
  Peter F.G. Schuur
  ,
  Geoffrey Kittredge
  ,
  Kevin Rinker
  ,
  William D. Regner
  ,
  Jeffrey P. Cunard
  ,
  Robert F. Quaintance, Jr.
  ,
  Richard F. Hahn
  ,
  Jasmine Ball
• The Private Equity Report
  Winter 2008
  Franci J. Blassberg
  ,
  Kevin Rinker
  ,
  Alan J. Davies
  ,
  James A. Kiernan III
  ,
  E. Drew Dutton
  ,
  Peter J. Loughran
  ,
  Margaret Andrews Davenport
  ,
  Jonathan R. Tuttle
  ,
  Nicholas F. Potter